About Nucleonics
Nucleonics is a Healthcare company based in Langhorne (United States) founded in 2001, and was acquired by Alnylam in December 2008. RNAi therapeutics for viral diseases including Hepatitis-B were developed. It operates in the Healthcare and Technology sectors. Nucleonics has raised $51.9 million across 3 funding rounds from investors including Alnylam, Oxford Finance and Burrill and Company. Nucleonics offers products and services including Hepatitis B Therapeutic Program, Hepatitis C Therapeutic Program, and DNA Delivery Technology. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is Nucleonics Inc. Its competitors include Adaptive Biotechnologies, Moderna and Denali Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Nucleonics was a clinical stage company focussed on developing RNAi therapeutics for viral and other diseases. It claims to include over 100 active patent filings, including 16 that have granted worldwide and 6 that have been granted in the U.S., Europe, or Japan. Its lead candidate NUC-B1000 is an RNAi-based therapy which was in phase 2 trials for Hepatitis-B. In December 2008, Alnylam acquired Nucelonics and its assets.
- Headquarters Langhorne, United States
- Stage Acquired
- SectorsHealthcareTechnology
- Email••••••••
- Website nucleonicsinc.com
- Acquired by Alnylam (Dec 2008)
- Legal Name Nucleonics Inc.
Products & Services of Nucleonics
Nucleonics offers a comprehensive portfolio of products and services, including Hepatitis B Therapeutic Program, Hepatitis C Therapeutic Program, and DNA Delivery Technology.
RNAi-based treatment targeting Hepatitis B virus
RNAi-based treatment for Hepatitis C genotypes
Proprietary system for efficient DNA vector delivery
Funding Insights of Nucleonics
Nucleonics has successfully raised a total of $51.9M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $2.7 million completed in October 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.9M
- Total Rounds 3
- Last Round Series B — $2.7M
- First Round $40.9M
(Apr 2004)
- Investors Count 8
All 3 funding rounds of Nucleonics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2004 | $2.7M | Series B | – | – | |
| Jun 2004 | $8.3M | Series B | – | – | |
| Apr 2004 | $40.9M | Series B | – | – |
9 investors in total: 9 institutional.
Investors in Nucleonics
Nucleonics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Alnylam, Oxford Finance and Burrill and Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
| quakerpartners.com | ||||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
| healthcap.eu | ||||
| anthemcapital.com | ||||
| poscobioventures.com | ||||
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | alnylam.com | Cambridge, United States |
Investor details for Nucleonics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Nucleonics
4 dated milestones of Nucleonics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Nucleonics is founded.
- Funding First funding round of $40.9M.
- Funding Latest funding round, Series B, of $2.7M.
- Exit Acquired by Alnylam.
Competitors of Nucleonics
Nucleonics has 3 listed competitors in our database, 3 of them funded. They include Adaptive Biotechnologies, Moderna and Denali Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. |
Detailed competitors of Nucleonics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Nucleonics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nucleonics
Nucleonics was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Nucleonics is headquartered in Langhorne, United States. It is registered at Langhorne, Pennsylvania, United States.
Nucleonics is a funded company, having raised a total of $51.9M across 3 funding rounds to date. The company's 1st funding round was a Series B of $40.9M, raised on Apr 2004.
Nucleonics was a clinical stage company focussed on developing RNAi therapeutics for viral and other diseases. It claims to include over 100 active patent filings, including 16 that have granted worldwide and 6 that have been granted in the U.S., Europe, or Japan. Its lead candidate NUC-B1000 is an RNAi-based therapy which was in phase 2 trials for Hepatitis-B. In December 2008, Alnylam acquired Nucelonics and its assets.
Nucleonics's top competitors include Moderna, Adaptive Biotechnologies and Denali Therapeutics.
Nucleonics offers Hepatitis B Therapeutic Program, Hepatitis C Therapeutic Program, and DNA Delivery Technology.
Nucleonics has 9 investors. Key investors include Alnylam, Oxford Finance, Burrill and Company, Quaker Partners Management, and SR One.
Nucleonics operates through Nucleonics Inc..
Yes. Nucleonics was acquired by Alnylam in December 2008.